Clinical Report: Update on Vevye and Access Initiatives for Dry Eye Disease

Overview

Vevye (cyclosporine ophthalmic solution 0.1%) has shown sustained efficacy and good tolerability for dry eye disease since its launch in January 2024. The Vevye Access for All initiative aims to reduce barriers to therapy, ensuring affordability and accessibility for eligible patients.

Background

Dry eye disease (DED) is a common condition that significantly impacts patients' quality of life. Traditional treatments, particularly cyclosporine-based products, have faced challenges related to tolerability and patient adherence. The introduction of Vevye represents a potential advancement in the management of DED, addressing both efficacy and tolerability concerns.

Data Highlights

No numerical data presented in the article.

Key Findings

• Vevye promotes corneal healing in as little as 15 days.
• 99.8% of patients reported no or only mild stinging and burning upon instillation.
• The Vevye Access for All initiative offers therapy for $59, eliminating prior authorization and reimbursement delays.
• Harrow's partnership with Cencora enhances access to Iheezo and Triesence for retinal specialists.
• Triesence is now eligible for separate reimbursement effective April 1, 2025, across various care settings.

Clinical Implications

Healthcare providers can confidently prescribe Vevye, knowing it has a favorable tolerability profile compared to previous cyclosporine formulations. The Vevye Access for All initiative may facilitate improved patient adherence to therapy by addressing financial barriers.

Conclusion

The advancements represented by Vevye and the associated access initiatives mark a significant step forward in the management of dry eye disease, potentially improving patient outcomes and satisfaction.

References

1. Harrow, Inc., Ophthalmology Management, 2024 -- Update on Vevye and Access Initiatives
2. The ASCO Post — Renowned Hematologist Mojtaba Akhtari, MD, Reflects on a New Era in Treating Blood Cancers
3. The ASCO Post — Renowned Hematologist Mojtaba Akhtari, MD, Reflects on a New Era in Treating Blood Cancers
4. Journal of Neuro-Oncology — Erratum: Analysis of Healthcare Use and Expenses in Patients with Intracranial Meningioma Over Extended Follow-Up Periods
5. retinal physician — PER-001 Shows Functional and Structural Improvement in DR
6. Dry Eye Syndrome Preferred Practice Pattern®
7. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study
8. Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials - Yuri Aleksander-Ivanov, Dillan Cunha Amaral, Lidia Cheidde, Gabriel Nery Lima, Carolina Carvalho Soares Valentim, Michel Sebba Chater, Denisse J. Mora-Paez, Jaime Guedes, 2025